ライフサイエンスコーパス: atrial tachyarrhythmia

1 -8.2 months (74% had a documented history of atrial tachyarrhythmias).

2 e, left ventricular systolic dysfunction, or atrial tachyarrhythmia.

3 iated with a higher risk of sudden death and atrial tachyarrhythmia.

4 and may serve as a source of the adrenergic atrial tachyarrhythmia.

5 tion into epicardial fat pads for preventing atrial tachyarrhythmias.

6 p = 0.04) and had a comparable incidence of atrial tachyarrhythmias.

7 ory of IAT or by the development of in-trial atrial tachyarrhythmias.

8 technique for managing children with JET and atrial tachyarrhythmias.

9 on occurred in 7 animals, simulating a rapid atrial tachyarrhythmias.

10 d points were recurrence of AF and organized atrial tachyarrhythmias.

11 (LAAI) may occur during catheter ablation of atrial tachyarrhythmias.

12 ears between patients with and those without atrial tachyarrhythmias.

13 ECNA) is an invariable trigger of paroxysmal atrial tachyarrhythmias.

14 morbidity and mortality rates from recurrent atrial tachyarrhythmias.

15 hom 19 had a history of documented sustained atrial tachyarrhythmias.

16 herapies to reduce the burden of spontaneous atrial tachyarrhythmias.

17 erapies for prevention and/or termination of atrial tachyarrhythmias.

18 ovel noncontact mapping system for assessing atrial tachyarrhythmias.

19 Eleven patients had atrial tachyarrhythmias: 10 of 11 had immediate success,

20 Reasons included the development of an atrial tachyarrhythmia (18%), loss of left ventricular c

21 ower heart rates were more likely to develop atrial tachyarrhythmias, a dual-chamber rate-modulated p

22 ers the risk of atrial fibrillation or other atrial tachyarrhythmias (AF/AT), or if postimplantation

23 riate therapy due to atrial fibrillation and atrial tachyarrhythmias, also evaluated as ATP or shock

24 and initial treatment of AF, coexistence of atrial tachyarrhythmia and (2) progression of paroxysmal

25 n the 52 of 269 patients who had episodes of atrial tachyarrhythmia and had >/=30 days of follow-up w

26 The outcomes measured were recurrence of atrial tachyarrhythmia and the incidence of adverse even

27 new molecular and mechanistic insights into atrial tachyarrhythmias and identifies Kir3.x as a promi

28 outcomes included symptomatic recurrences of atrial tachyarrhythmias and quality of life measures ass

29 Early recurrences (ERs) of atrial tachyarrhythmia are common after catheter ablatio

30 Atrial tachyarrhythmias are a complication of Fontan sur

31 drugs resulted in a lower rate of recurrent atrial tachyarrhythmias at 2 years.

32 f cardiac resynchronization therapy (CRT) on atrial tachyarrhythmia (AT) susceptibility in patients w

33 Secondary endpoints included freedom from atrial tachyarrhythmias (AT) at 6 and 12 months, peripro

34 e into a subsequent reduction in the risk of atrial tachyarrhythmias (AT).

35 However, atrial tachyarrhythmias (ATA) are a common early complic

36 nts, 37 of whom also demonstrated persistent atrial tachyarrhythmias (ATAs).

37 upporting an association between subclinical atrial tachyarrhythmias (ATs) detected by cardiac implan

38 rocardiogram (PSAECG) for risk assessment of atrial tachyarrhythmias (ATs) in patients after Fontan o

39 ventricular tachyarrhythmias have documented atrial tachyarrhythmias before implantation.

40 erence was observed in 12-month freedom from atrial tachyarrhythmias between an index ablative approa

41 atrial therapies resulted in a reduction of atrial tachyarrhythmia burden from a mean of 58.5 to 7.8

42 hyarrhythmias had a significant reduction in atrial tachyarrhythmia burden with use of atrial pacing

43 the effectiveness and safety of terminating atrial tachyarrhythmias clinically.

44 athogenic mutation in a familial syndrome of atrial tachyarrhythmia, conduction system disease (CSD),

45 rimary outcome event, 11 had had subclinical atrial tachyarrhythmias detected by 3 months, and none h

46 By 3 months, subclinical atrial tachyarrhythmias detected by implanted devices ha

47 ients with and those without device-detected atrial tachyarrhythmias during the first year.

48 patients for 3 months to detect subclinical atrial tachyarrhythmias (episodes of atrial rate >190 be

49 vein isolation (PVI) as early recurrence of atrial tachyarrhythmia (ERAT) may be due to transient pr

50 ablation resulted in better 2-year organized atrial tachyarrhythmia-free survival (71% [62%-79%] vers

51 Organized atrial tachyarrhythmia-free survival was similar after S

52 as (junctional ectopic tachycardia [JET] and atrial tachyarrhythmias) frequently complicate recovery

53 Patients with atrial tachyarrhythmia >/=30 s within the 3-month blanki

54 patients with a standard ICD indication and atrial tachyarrhythmias had a significant reduction in a

55 nts who had the Fontan procedure, those with atrial tachyarrhythmias had longer P-wave duration (159+

56 Patients with atrial tachyarrhythmias had longer paced (153+/-29 versu

57 xis decreases the incidence of postoperative atrial tachyarrhythmias have had mixed results and were

58 e the effect of both history of intermittent atrial tachyarrhythmias (IAT) and in-trial IAT on the ri

59 ciation with a higher incidence of sustained atrial tachyarrhythmia, implying that sinus node dysfunc

60 There was recurrence of atrial tachyarrhythmia in 222 of 785 (28%) patients who

61 can suppress sympathetic outflow and reduce atrial tachyarrhythmias in ambulatory dogs.

62 ies and reduces the incidences of paroxysmal atrial tachyarrhythmias in ambulatory dogs.

63 entricular rate during postoperative JET and atrial tachyarrhythmias in our young canine open heart s

64 iods, was associated with the development of atrial tachyarrhythmias in pacemaker patients.

65 icacy of novel pacing therapies for treating atrial tachyarrhythmias in patients receiving a dual-cha

66 become the treatment strategy of choice for atrial tachyarrhythmias in patients with congenital hear

67 based atrial pacing for treating spontaneous atrial tachyarrhythmias in patients with implantable car

68 the implantation of an ICD and 2 episodes of atrial tachyarrhythmias in the preceding year received a

69 perform high-resolution multisite mapping of atrial tachyarrhythmias in vivo.

70 anges of atrial electrophysiology and induce atrial tachyarrhythmias, including atrial tachycardia an

71 Atrial tachyarrhythmia is a common cause of morbidity an

72 The mechanism of the adrenergic atrial tachyarrhythmia is unclear.

73 has been implicated in the genesis of focal atrial tachyarrhythmias, its gross anatomic and microsco

74 In 8 of 9 patients with >1 event, atrial tachyarrhythmia, itself a known risk factor for m

75 Patients with atrial tachyarrhythmias late after Fontan operation have

76 In patients with CHD, atrial tachyarrhythmias may result from IART or IDAF.

77 The time to the first documented atrial tachyarrhythmia of more than 30 seconds (symptoma

78 end point was freedom from recurrence of any atrial tachyarrhythmia, outside a 90-day blanking period

79 abnormality on the ECG and a diagnosis of an atrial tachyarrhythmia predict sudden death.

80 All patients had medically refractory atrial tachyarrhythmias, primarily atrial fibrillation (

81 Atrial tachyarrhythmias recurred in 28 PVI-only group pa

82 n ostial PVI in achieving freedom from total atrial tachyarrhythmia recurrence at long-term follow-up

83 , 61%) or persistent atrial fibrillation and atrial tachyarrhythmia recurrences despite previous succ

84 MIL ablation may reduce organized atrial tachyarrhythmia recurrences.

85 ], 1.24 to 8.78) and a clinical diagnosis of atrial tachyarrhythmia (relative risk, 5.18; 95% CI, 2.2

86 Subclinical atrial tachyarrhythmias remained predictive of the prima

87 toms, but the rates of exercise intolerance, atrial tachyarrhythmias, right ventricular dysfunction,

88 defibrillators with recurrent ventricular or atrial tachyarrhythmias should not interfere with proper

89 ary artery bypass graft provided substantial atrial tachyarrhythmia suppression both early as well as

90 systems can automatically detect and record atrial tachyarrhythmias that may be asymptomatic.

91 hundred and forty-four patients with CHD and atrial tachyarrhythmias undergoing radiofrequency cathet

92 were "CPAP nonusers." The recurrence of any atrial tachyarrhythmia, use of antiarrhythmic drugs, and

93 One-year freedom from symptomatic atrial tachyarrhythmia was 77.2% in patients without ER

94 The induced atrial tachyarrhythmia was suppressed in nine patients (

95 ystemic embolism associated with subclinical atrial tachyarrhythmias was 13%.

96 recurrences of atrial fibrillation or other atrial tachyarrhythmias was evaluated at the end of the

97 Subclinical atrial tachyarrhythmias were associated with an increase

98 Second, the patients with atrial tachyarrhythmias who had the Fontan procedure had

99 3 +/- 12 ms) in patients with suppression of atrial tachyarrhythmia with dual-site atrial pacing comp

100 Subclinical atrial tachyarrhythmias, without clinical atrial fibrill